Design, synthesis, antiviral and cytotoxic evaluation of novel acyclic phosphonate nucleotide analogues with a 5,6-dihydro-1H-[1,2,3]triazolo[4,5-d]pyridazine-4,7-dione system

Abstract

Abstract

A series of diethyl 2-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-yl)alkylphosphonates was synthesised from ω-azidoalkylphosphonates and dimethyl acetylenedicarboxylate and was further transformed into the respective diamides, dihydrazides, and 5,6-dihydro-1H-[1,2,3]triazolo[4,5-d]pyridazine-4,7-diones as phosphonate analogues of acyclic nucleosides having nucleobases replaced with substituted 1,2,3-triazoles. All compounds containing P–C–C–triazole or P–C–C–CH₂–triazole moieties exist in single conformations in which the diethoxyphosphoryl and substituted 1,2,3-triazolyl or substituted (1,2,3-triazolyl)methyl groups are oriented anti. All phosphonates were evaluated in vitro for activity against a variety of DNA and RNA viruses. None of the compounds were endowed with antiviral activity. They were not cytostatic at 100 μM.

Graphical abstract

Electronic supplementary material

The online version of this article (doi:10.1007/s00706-013-1137-x) contains supplementary material, which is available to authorized users.

Introduction

In the past two decades acyclic nucleoside phosphonates (ANPs) have become one of the most important classes of antiviral drugs [1]. Three of them (adefovir, cidofovir, tenofovir; Fig. 1) have been marketed for treatment of viral infection caused by HIV, HBV, HSV and other DNA viruses [2–5]. The concept of acyclic nucleosides is based on the assumption that an acyclic moiety most often bearing an oxygen atom mimics the furanose ring at least partially. Acyclic nucleoside phosphonates require conversion in vivo to their triphosphate metabolites to become active [2, 6]. The replacement of the natural phosphate moiety by a phosphonate group makes analogues less susceptible to enzymatic hydrolysis [7, 8].

Fig. 1.

ANPs marketed for treatment of viral infections

Further studies in this field brought a new generation of nucleotide/nucleoside analogues in which natural nucleobases were modified as exemplified by the 2,4-diaminopyrimidine framework present in antiviral HPMPO-DAPy and PMPO-DAPy [9–11] and the 1,2,4-triazole ring in ribavirin (Fig. 2) [12].

Fig. 2.

Structures of HPMPO-DAPy, PMPO-DAPy and ribavirin

The antiviral activity of ribavirin stimulated interest in replacing the 1,2,4-triazole system with an isomeric 1,2,3-triazole ring because several 1,2,3-triazoles exhibit antibacterial [13–15], antifungal [15–17], anticancer [18–20], anti-inflammatory [21, 22] and antiviral [23–26] properties. It was found that carbocyclic analogues 1 and phosphonocarbocyclic analogues 2 of ribavirin displayed antiviral activity against HIV-1 (Fig. 3) [27].

Fig. 3.

Antiviral analogues of ribavirin having the 1,2,3-triazole ring

Furthermore, preliminary structure–activity relationship evaluation of 1,2,3-triazole nucleoside phosphonates 3 and 4 suggested that this scaffold could be further optimised to afford selective inhibitors of HCV replication (Fig. 4) [28].

Fig. 4.

1,2,3-Triazole nucleoside phosphonates as potential inhibitors of HCV replication

On the other hand, it was reported that nucleoside analogues 5 and 6 containing the 5,6-dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione ring instead of the natural purine framework exhibited antiviral activity by inhibition of a viral helicase from West Nile Virus (WNV) and HCV (Fig. 5). These observations may be useful in designing a lead structure for the development of new classes of antiviral agents [29].

Fig. 5.

Cyclic nucleoside analogues based on the 5,6-dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione framework

Based on the active compounds already discussed, a novel series of phosphonate analogues 11 having the 5,6-dihydro-1H-[1,2,3]triazolo[4,5-d]pyridazine-4,7-dione system was designed as potential antiviral agents (Scheme 1). Furthermore, because their immediate precursor dihydrazides 10 as well as diamides 9 share several common structural features with ribavirin, they also may show antiviral activity. The key step of our synthetic plan involves the 1,3-dipolar cycloaddition of dimethyl acetylenedicarboxylate and ω-azidoalkylphosphonates 7 which contain structurally diversified alkyl chains to provide the intermediate diesters 8.

Results and discussion

Chemistry

The 1,2,3-triazoles 8a–8d and 8f were synthesised in 64–98 % yield employing the Huisgen 1,3-dipolar cycloaddition of the corresponding azidophosphonates 7 and dimethyl acetylenedicarboxylate at 110 °C in the same way as the known compounds 8e and 8g [30, 31]. They were finally purified either by chromatography on a silica gel column or by crystallisation (Scheme 1).

The required azidoalkylphosphonates 7a–7e and 7g have already been described in the literature [30, 32–36]. Azidophosphonate 7f was obtained in the Abramov reaction [37, 38] from 3-azidopropanal [39] and diethyl phosphite in 34 % yield (Scheme 2). It was found that 3-azidopropanal is unstable in the presence of triethylamine used as a catalyst in this reaction. For this reason only 0.4 equiv. of diethyl phosphite was applied to avoid tedious separation of 7f from the reaction mixture.

The diamides 9a–9g were obtained from diesters 8a–8g by ammonolysis according to a standard protocol (Scheme 1) [6, 40]. The crude products were subjected to column chromatography on silica gel and finally purified by crystallisation to give 9a–9g in 37–61 % yields. The ¹H NMR spectra of diamides 9a–9g in chloroform-d confirmed the nonequivalence of protons from the carbamoyl groups because in the 6.0–10.8 ppm region four broad singlets were always observed.

The diesters 8a–8g were also converted to the corresponding dihydrazides 10a–10g with hydrazine hydrate (Scheme 1). Preliminary attempts at synthesising dihydrazide 10a followed the literature procedure [41] and showed that refluxing phosphonate 8a and hydrazine hydrate in ethanolic solution for 5 h led to the formation of several products. The ³¹P NMR spectrum of the reaction mixture revealed the presence of the expected phosphonate 10a (76 %), bicyclic 1,2,3-triazolopyridazinedione 11a (11 %) and their monodealkylated counterparts 12a and 13a (10 and 3 %, respectively) (Fig. 6). When hydrazinolysis of the diester 8a was conducted for 2 h only phosphonates 10a (79 %) and 11a (21 %) were produced. For this reason syntheses of dihydrazides 10b–10g were performed under the same conditions. However, it appeared that for compounds 8c and 8g significant dealkylation still occurred. In both cases the respective crude reaction mixtures contained almost 50 % of by-products. Purifications on silica gel columns and crystallisations gave dihydrazides 10a–10g in 28–66 % yields.

Fig. 6.

Compounds 12a and 13a

Finally, heating dihydrazides 10a–10g with 10 % hydrochloric acid for 2.5 h gave [1,2,3]triazolo[4,5-d]pyridazine-4,7-diones 11a–11g (Scheme 1) in 30–66 % yields [41].

Conformational analysis

Detailed analyses of ¹H and ¹³C NMR spectral data revealed conformational preferences of phosphonates described in this paper. Compounds 8a–11a contain an 1,2-substituted ethylene fragment which does not freely rotate around a C–C bond because their ¹H NMR spectra display AA′XX′P patterns. A similar spectrum was also noticed for 2-azidoethylphosphonate [31]. Antiperiplanar disposition of the diethoxyphosphoryl groups and substituted 1,2,3-triazoles 14a (Fig. 7) was proved by the presence of two identical ³ J(P–H_X) = 10.5 Hz couplings which were calculated from the ¹H{³¹P} NMR spectrum of 8a.

Fig. 7.

Preferred conformations of the phosphonates described in this study

In the ¹H NMR spectra of compounds 8g, 10g, and 11g three hydrogen atoms attached to the two-carbon linker appeared as deceptively simple but very similar ABXP spectral patterns. However, the relevant ³ J(H1–H2a) and ³ J(H1–H2b) coupling constants were precisely calculated (10.2 and 3.6 Hz, respectively) from the ¹H NMR spectrum of diamide 9g. These values [42] together with small couplings for ³ J(P–H2a) and ³ J(P–H2b) [43, 44] allowed us to unequivocally establish 14g (Fig. 7) as the preferred conformation of phosphonate 9g although other phosphonates from this series very likely adopt the same anti conformation.

Large values (16.9–19.2 Hz) of ³ J(P–CC–C3) [44–46] observed in the ¹³C NMR spectra of phosphonates 8–11 containing a three-carbon fragment between the phosphorus atom and the 1,2,3-triazole ring (series b, e, and f) evidenced the preference of antiperiplanar conformations 14b, 14e, and 14f (Fig. 7) for these compounds. This conclusion was further supported by vicinal H1–H2 couplings calculated for 2- and 1-hydroxyphosphonates (series e and f) which clearly indicated gauche (3.0–3.6 Hz) and anti (9.6–10.8 Hz) arrangements of the respective H–C1C2–H protons.

Although values (9.3–12.1 Hz) of ³ J(P–C–O–C) were easily extracted from the ¹³C NMR spectra of phosphonates 8–11 (series c) they could not be unequivocally applied in the estimation of the extent to which rotation around the PC–OC bond is hindered because the angular dependence of ³ J(P–C–O–C) has not been established so far. However, the rotation around the OC–CN bond is not restricted because vicinal H₂C–CH₂ coupling constants observed for phosphonates 8c–11c fall in the 4.8–5.2 Hz range. On the other hand, on the basis of the values of ³ J(HC–CH) found for PH₂C–CH₂O and OH₂C–CH₂N units (7.2–7.8 and 5.1–5.7 Hz, respectively), full conformational freedom within a five-atom linker in phosphonates 8–11 (series d) is anticipated.

Antiviral activity evaluation

The synthesised compounds 9a–9g, 10a–10g, and 11a–11g were evaluated for their antiviral activities against a wide variety of DNA and RNA viruses using the following cell-based assays: (a) human embryonic lung (HEL) cell: herpes simplex virus-1 (KOS), herpes simplex virus-2 (G), herpes simplex virus-1 (TK⁻ ACV^r KOS), vaccinia virus, vesicular stomatitis virus, varicella-zoster virus (TK⁺ VZV strain OKA and TK^¯ VZV strain 07-1) and cytomegalovirus (CMV) (strain AD-169 and Davis); (b) CEM cell cultures: human immunodeficiency virus-1 (HIV-1) and HIV-2; (c) Vero cell cultures: para-influenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus; (d) HeLa cell cultures: vesicular stomatitis virus, Coxackie virus B4 and respiratory syncytial virus; (e) Crandel-Rees feline kidney (CRFK) cell cultures: feline corona virus (FIPV) and feline herpes virus (FHV) and (f) Madin Darby Canine kidney (MDCK) cell culture: influenza A virus H1N1 subtype A/PR/8, influenza H3N2 subtype A/HK/7/87 and influenza B virus (B/HK/5/72). Ganciclovir, cidofovir, acyclovir, brivudin, (S)-9-(2,3-dihydroxypropyl)adenine [(S)-DHPA], ribavirin, oseltamivir carboxylate, amantadine and rimantadine were used as the reference compounds. The antiviral activity was expressed as the EC₅₀: the compound concentration required to reduce virus plaques formation (VZV, CMV) by 50 % or to reduce virus-induced cytopathogenicity by 50 % (other viruses). None of the compounds showed appreciable antiviral activity at subtoxic concentrations.

Evaluation of cytotoxicity

The cytotoxicity of the tested compounds towards the uninfected host cells was defined as the minimum cytotoxic concentration (MMC) that causes a microscopically detectable alteration of normal cell morphology. The 50 % cytotoxic concentration (CC₅₀), i.e. causing a 50 % decrease in cell viability, was determined using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay system. None of the tested compounds affected the cell morphology of Vero, HEL, HeLa or CRFK cells (MCC or CC₅₀) at compound concentrations up to 100 μM. They were also not cytostatic against murine leukemia and human CEM and HeLa cells at 100 μM.

Conclusions

Phosphonylated 1,2,3-triazoles 8a–8g were obtained in good to excellent yields by 1,3-dipolar cycloaddition between ω-azidophosphonates 7a–7g and dimethyl acetylenedicarboxylate. New series of diamides 9a–9g, dihydrazides 10a–10g and 1,2,3-triazolopyridazinediones 11a–11g were efficiently synthesised as phosphonate analogues of acyclic nucleosides in which nucleobases were replaced by substituted 1,2,3-triazoles.

Compounds 8–11 (series a, b, e, f, g) exist in single conformations in which diethoxyphosphoryl and substituted 1,2,3-triazolyl (series a and b) or (1,2,3-triazolyl)methyl groups (series e, f, g) prefer the anti orientation.

All synthesised compounds were evaluated for their antiviral activity against DNA and RNA viruses and were inactive. None of the compounds were cytotoxic (Vero, HEL, HeLa) or cytostatic (L1210, CEM, HeLa) at a concentration up to 100 μM.

Experimental

The ¹H NMR spectra were recorded in CDCl₃, CD₃OD or D₂O on the following spectrometers: Varian Mercury-300 and Bruker Avance III (600 MHz) with TMS as an internal standard; chemical shifts δ in ppm with respect to TMS; coupling constants J in Hz. The ¹³C NMR spectra were recorded for CDCl₃, CD₃OD or D₂O solutions on Varian Mercury-300 and Bruker Avance III (600 MHz) machines at 75.5 and 150.5 MHz, respectively. The ³¹P NMR spectra were recorded in CDCl₃, CD₃OD or D₂O on Varian Mercury-300 and Bruker Avance III (600 MHz) spectrometers at 121.5 and 243 MHz, respectively.

IR spectra were measured on an Infinity MI-60 FT-IR spectrometer. Melting points were determined on the Boetius apparatus. Elemental analyses were performed by the microanalytical laboratory of the host institution on Perkin Elmer PE 2400 CHNS analyzer and the results were found to be in good agreement (±0.3 %) with the calculated values.

The following absorbents were used: column chromatography, Merck silica gel 60 (70–230 mesh); analytical TLC, Merck TLC plastic sheets, silica gel 60 F₂₅₄. TLC plates were developed in chloroform–methanol solvent systems. Visualization of spots was effected with iodine vapours. All solvents were dried according to standard literature methods.

Diethyl 3-azido-1-hydroxypropylphosphonate (7f, C₇H₁₆N₃O₄P)

A mixture of 5.77 g 3-azidopropanal [39] (0.0582 mol), 3.0 cm³ diethyl phosphite (0.023 mol) and 0.81 cm³ triethylamine (0.0058 mol) was stirred at 5 °C for 24 h. The crude product was subjected to chromatography on silica gel with chloroform/methanol (100:1 and 50:1, v/v) to give a yellow oil (4.671 g, 34 %). IR (film): $\overline{V}$ = 3,272, 2,985, 2,934, 2,911, 2,874, 2,102, 1,227, 1,028 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.35 (t, J = 7.1 Hz, 6H, 2 × POCH₂CH ₃), 1.87–2.06 (m, 3H, CH₂, OH), 3.55 (t, J = 6.3 Hz, 2H, CH ₂N₃), 4.01 (dt, J = 9.8, 4.6 Hz, 1H, H-1), 4.12–4.24 (m, 4H, 2 × POCH ₂CH₃) ppm; ¹³C NMR (CDCl₃, 75.5 MHz): δ = 16.6 and 16.7 (2 d, J = 5.4 Hz, POCC), 30.8 (d, J = 2.6 Hz, C-2), 47.7 (d, J = 15.5 Hz, C-3), 62.9 and 63.2 (2 d, J = 7.2 Hz, POC), 64.6 (d, J = 164.6 Hz, C-1) ppm; ³¹P NMR (CDCl₃, 121.5 MHz): δ = 25.28 ppm.

Synthesis of 1,2,3-triazoles 8a–8g (general procedure)

A solution of azidophosphonate 7a–7g (1.00 mmol) and dimethyl acetylenedicarboxylate 13 (1.00 mmol) in 4 cm³ toluene was refluxed for 4 h. The reaction mixtures were concentrated to dryness to leave yellow oils which were purified on silica gel columns with chloroform/methanol (100:1, v/v) or were crystallised to give 1,2,3-triazoles 8a–8g.

Diethyl 2-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-yl)ethylphosphonate (8a, C₁₂H₂₀N₃O₇P)

From 0.450 g azidophosphonate 7a (2.17 mmol) and 0.309 g dimethyl acetylenedicarboxylate 13 (2.17 mmol) phosphonate 8a was obtained as a yellowish oil (0.674 g, 89 %) after chromatography on a silica gel column with chloroform/methanol (100:1, v/v). IR (film): $\overline{V}$ = 3,462, 2,985, 2,958, 1,736, 1,468, 1,447, 1,225, 1,140, 1,060, 1,025, 957 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.33 (t, J = 7.1 Hz, 6H, CH ₃CH₂OP), 2.40–2.52 (m, 2H, PCH₂), 3.98 (s, 3H, OCH₃), 4.02 (s, 3H, OCH₃), 4.08–4.18 (m, 4H, CH₃CH ₂OP), 4.82–4.91 (m, 2H, CH₂N) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.6 (d, J = 5.7 Hz, CCOP), 27.2 (d, J = 140.6 Hz, PC), 45.4 (s, PCCN), 52.9 (s, OCH₃), 53.7 (s, OCH₃), 62.4 (d, J = 6.3 Hz, CCOP), 129.8 and 140.2 (2 s, C=C), 158.6 and 160.4 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 25.9 ppm.

Diethyl 3-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-yl)propylphosphonate (8b, C₁₃H₂₂N₃O₇P)

From 0.785 g azidophosphonate 7b (3.565 mmol) and 0.507 g dimethyl acetylenedicarboxylate 13 (3.565 mmol) phosphonate 8b was obtained as a yellowish oil (1.067 g, 83 %) after chromatography on a silica gel column with chloroform/methanol (100:1, v/v). IR (film): $\overline{V}$ = 2,953, 2,836, 1,736, 1,463, 1,226, 1,030 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.34 (t, J = 7.1 Hz, 6H, CH ₃CH₂OP), 1.72–1.84 (m, 2H, PCH₂CH ₂), 2.16–2.31 (m, 2H, PCH ₂), 4.00 (s, 3H, OCH₃), 4.03 (s, 3H, OCH₃), 4.05–4.18 (m, 4H, CH₃CH ₂OP), 4.71 (t, J = 7.1 Hz, 2H, CH₂N) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.5 (d, J = 6.0 Hz, POCC), 22.6 (d, J = 143.1 Hz, PC), 23.5 (d, J = 4.3 Hz, PCC), 50.4 (d, J = 16.9 Hz, PCCC), 52.7 (s, OCH₃), 53.2 (s, OCH₃), 61.8 (d, J = 6.3 Hz, POC), 129.7 and 139.8 (2 s, C=C), 158.6 and 160.3 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 30.7 ppm.

Diethyl 2-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-yl)ethoxymethylphosphonate (8c, C₁₃H₂₂N₃O₈P)

From 1.027 g azidophosphonate 7c (4.330 mmol) and 0.615 g dimethyl acetylenedicarboxylate 13 (4.330 mmol) phosphonate 8c was obtained as a yellowish oil (1.538 g, 93 %) after chromatography on a silica gel column with chloroform/methanol (100:1, v/v). IR (film): $\overline{V}$ = 3,459, 2,983, 2,957, 2,908, 1,732, 1,462, 1,225, 1,117, 1,060, 1,027, 960 cm⁻¹; ¹H NMR (CDCl₃, 600 MHz): δ = 1.31 (t, J = 7.0 Hz, 6H, CH ₃CH₂OP), 3.74 (d, J = 7.9 Hz, 2H, PCH₂), 3.98 (s, 3H, OCH₃), 4.02 (s, 3H, OCH₃), 4.02 (t, J = 5.2 Hz, 2H, OCH ₂CH₂N), 4.08–4.13 (m, 4H, CH₃CH ₂OP), 4.86 (t, J = 5.2 Hz, 2H, OCH₂CH ₂N) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.5 (d, J = 5.7 Hz, POCC), 49.8 (s, CN), 52.8 (s, OCH₃), 53.5 (s, OCH₃), 62.6 (d, J = 6.5 Hz, POCC), 65.2 (d, J = 164.7 Hz, PC), 71.0 (d, J = 9.3 Hz, PCOC), 131.0 and 139.6 (2 s, C=C), 158.8 and 160.3 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 243 MHz): δ = 20.04 ppm.

Diethyl 2-[2-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-yl)ethoxy]ethylphosphonate (8d, C₁₄H₂₄N₃O₈P)

From 0.647 g azidophosphonate 7d (2.68 mmol) and 0.382 g dimethyl acetylenedicarboxylate 13 (2.68 mmol) phosphonate 8d (1.030 g, 98 %) was obtained as a yellowish oil. The crude product was sufficiently pure and was used in the next step without further purification. IR (film): $\overline{V}$ = 3,459, 2,983, 2,957, 2,909, 1,736, 1,466, 1,229, 1,118, 1,063, 1,027, 963 cm⁻¹; ¹H NMR (CDCl₃, 600 MHz): δ = 1.32 (t, J = 7.1 Hz, 6H, CH ₃CH₂OP), 2.00 (dt, J = 15.3, 7.7 Hz, 2H, PCH₂), 3.63 (dt, J = 10.4, 7.7 Hz, 2H, PCH₂CH ₂O), 3.82 (t, J = 5.2 Hz, 2H, OCH ₂CH₂N), 4.00 (s, 3H, OCH₃), 4.01 (s, 3H, OCH₃), 4.05–4.12 (m, 4H, CH₃CH ₂OP), 4.82 (t, J = 5.2 Hz, 2H, OCH₂CH ₂N) ppm; ¹³C NMR (CDCl₃, 150 MHz): δ = 16.3 (d, J = 5.7 Hz, POCC), 26.7 (d, J = 139.3 Hz, PC), 49.8 (s, OCCN), 52.6 (s, OCH₃), 53.3 (s, OCH₃), 61.6 (d, J = 6.4 Hz, CCOP), 65.3 (s, PCC), 68.7 (s, OCCN), 131.4 and 139.5 (2 s, C=C), 159.1 and 160.3 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 243 MHz): δ = 27.58 ppm.

Diethyl 1-hydroxy-3-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-yl)propylphosphonate (8f, C₁₃H₂₂N₃O₈P)

From 0.560 g azidophosphonate 7f (2.36 mmol) and 0.335 g dimethyl acetylenedicarboxylate 13 (2.36 mmol) phosphonate 8f (0.850 g, 95 %) was obtained as a white amorphous solid after chromatography on a silica gel column with chloroform/methanol (100:1, v/v). M.p.: 107–109 °C; IR (film): $\overline{V}$ = 3,420, 3,218, 3,081, 2,985, 2,878, 1,675, 1,451, 1,280, 1,223, 1,030, 970 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.33 and 1.34 (2 t, J = 7.2 Hz, 6H, CH ₃CH₂OP), 2.28–2.47 (m, 2H, PCCH ₂), 3.70 (dd, J = 6.0, 5.1 Hz, 1H, OH), 3.84 (dddd, J = 10.5, 6.3, 6.0, 3.3 Hz, 1H, PCH), 3.98 (s, OCH₃), 4.00 (s, OCH₃), 4.10–4.22 (m, 4H, CH₃CH ₂OP), 4.75–4.90 (m, 2H, CH₂N) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.6 and 16.7 (2 d, J = 5.4 Hz, CCOP), 31.9 (d, J = 3.2 Hz, PCC), 47.2 (d, J = 16.3 Hz, PCCC), 52.8 (s, OCH₃), 53.6 (s, OCH₃), 63.0 and 63.3 (2 d, J = 7.3 Hz, CCOP), 64.6 (d, J = 164.2 Hz, PC), 130.3 and 139.7 (2 s, C=C), 158.8 and 160.4 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 23.5 ppm.

Synthesis of diamides 9a–9g (general procedure)

To a solution of the diester 8a–8g (1.00 mmol) in 14 cm³ ethanol 16 cm³ was added aqueous ammonia. The reaction mixtures were stirred at room temperature for 24 h. Ethanol and excess ammonia were evaporated in vacuo. Diamides 9a–9g were purified on silica gel columns with chloroform/methanol or by crystallisation.

Diethyl 2-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)ethylphosphonate (9a, C₁₀H₁₈N₅O₅P)

From 0.165 g diester 8a (0.472 mmol) diamide 9a was obtained as a white amorphous solid (0.065 g, 42 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, v/v) followed by crystallisation from ethanol/diethyl ether. M.p.: 172–173 °C; IR (KBr): $\overline{V}$ = 3,428, 3,228, 3,113, 2,986, 2,932, 1,687, 1,451, 1,221, 1,023 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.34 (t, J = 6.9 Hz, 6H, CH ₃CH₂OP), 2.41–2.53 (m, 2H, PCH₂), 4.09–4.21 (m, 4H, CH₃CH ₂OP), 5.08–5.17 (m, 2H, CH₂N), 6.01 (s, 2H, NH₂), 7.58 (s, 1H, NH), 10.77 (s, 1H, NH) ppm; ¹³C NMR (CD₃OD, 75 MHz): δ = 16.8 (d, J = 6.0 Hz, CCOP), 27.3 (d, J = 140.3 Hz, PC), 47.2 (s, PCCN), 63.8 (d, J = 6.6 Hz, CCOP), 132.1 and 140.4 (2 s, C=C), 160.3 and 165.2 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 26.5 ppm.

Diethyl 3-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)propylphosphonate (9b, C₁₁H₂₀N₅O₅P)

From 0.114 g diester 8b (0.314 mmol) diamide 9b was obtained as a white amorphous solid (0.070 g, 61 %) after chromatography on a silica gel column with chloroform/methanol (50:1, v/v) and crystallisation from ethanol. M.p.: 143–144 °C; IR (KBr): $\overline{V}$ = 3,455, 3,270, 2,984, 2,909, 1,694, 1,629, 1,592, 1,454, 1,205, 1,018, 961 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.31 (t, J = 6.9 Hz, 6H, CH ₃CH₂OP), 1.74–1.86 (m, 2H, PCH₂CH ₂), 2.18–2.32 (m, 2H, PCH₂), 4.04–4.16 (m, 4H, CH₃CH ₂OP), 4.98 (t, J = 6.9 Hz, 2H, CH₂N), 6.13 (s, 1H, NH), 6.25 (s, 1H, NH), 7.62 (s, 1H, NH), 10.79 (s, 1H, NH) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.7 (d, J = 6.6 Hz, CCOP), 23.0 (d, J = 141.9 Hz, PC), 23.8 (d, J = 4.3 Hz, PCC), 51.8 (d, J = 19.2 Hz, PCCC), 62.0 (d, J = 6.6 Hz, CCOP), 130.7 and 138.7 (2 s, C=C), 158.6 and 163.7 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 31.4 ppm.

Diethyl [2-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)ethoxy]methylphosphonate (9c, C₁₁H₂₀N₅O₆P)

From 0.280 g diester 8c (0.738 mmol) diamide 9c was obtained as a white amorphous solid (0.139 g, 54 %) after chromatography on a silica gel column with chloroform/methanol (50:1, v/v). M.p.: 100–101 °C; IR (KBr): $\overline{V}$ = 3,361, 3,259, 3,110, 2,990, 2,959, 2,901, 1,689, 1,613, 1,454, 1,303, 1,219, 1,118, 1,048, 1,019, 967, 943 cm⁻¹; ¹H NMR (CD₃OD, 600 MHz): δ = 1.29 (t, J = 7.1 Hz, 6H, CH ₃CH₂OP), 3.89 (d, J = 8.5 Hz, 2H, PCH₂), 4.06 (t, J = 5.2 Hz, 2H, OCH ₂CH₂N), 4.06–4.10 (m, 4H, CH₃CH ₂OP), 5.14 (t, J = 5.2 Hz, 2H, CH₂N) ppm; ¹³C NMR (CD₃OD, 150 MHz): δ = 15.3 (d, J = 5.9 Hz, CCOP), 50.3 (s, CN), 62.8 (d, J = 6.5 Hz, CCOP), 64.0 (d, J = 164.7 Hz, PC), 71.1 (d, J = 11.9 Hz, PCOC), 131.0 and 139.0 (2 s, C=C), 159.1 and 163.9 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 243 MHz): δ = 21.3 ppm.

Diethyl 2-[2-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)ethoxy]ethylphosphonate (9d, C₁₂H₂₂N₅O₆P)

From 0.264 g diester 8d (0.671 mmol) diamide 9d was obtained as a white amorphous solid (0.090 g, 37 %) after chromatography on a silica gel column with chloroform/methanol (50:1, v/v) and crystallisation from ethyl acetate. M.p.: 102–103 °C; IR (KBr): $\overline{V}$ = 3,400, 3,306, 3,214, 2,986, 2,906, 1,672, 1,608, 1,453, 1,245, 1,109, 1,024, 961 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.31 (t, J = 6.9 Hz, 6H, CH ₃CH₂OP), 2.05 (dt, J = 15.3, 7.8 Hz, 2H, PCH₂), 3.69 (dt, J = 11.1, 7.8 Hz, 2H, PCH₂CH ₂O), 3.91 (t, J = 5.4 Hz, 2H, OCH ₂CH₂N), 4.01–4.12 (m, 4H, CH₃CH ₂OP), 5.11 (t, J = 5.4 Hz, 2H, OCH₂CH ₂N), 6.00 (s, 1H, NH), 6.07 (s, 1H, NH), 7.60 (s, 1H, NH), 10.77 (s, 1H, NH) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.6 (d, J = 6.0 Hz, CCOP), 26.9 (d, J = 139.1 Hz, PC), 51.0 (s, OCCN), 61.9 (d, J = 6.3 Hz, CCOP), 65.0 (s, PCCO), 69.1 (s, OCCN), 130.9 and 139.7 (2 s, C=C), 158.7 and 163.7 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 29.2 ppm.

Diethyl 3-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)-2-hydroxypropylphosphonate (9e, C₁₁H₂₀N₅O₆P)

From 0.145 g diester 8e (0.382 mmol) diamide 9e was obtained as a white amorphous solid (0.060 g, 45 %) after chromatography on a silica gel column with chloroform/methanol (50:1, v/v) and crystallisation from methanol. M.p.: 142–143 °C; IR (KBr): $\overline{V}$ = 3,428, 3,308, 3,034, 2,988, 1,686, 1,667, 1,599, 1,443, 1,375, 1,293, 1,113, 1,083, 1,055, 1,029, 960 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz): δ = 1.32 (t, J = 7.2 Hz, 6H, CH ₃CH₂OP), 2.06 (ddd, J = 22.8, 15.3, 7.8 Hz, 1H, PCH _aH_b), 2.18 (ddd, J = 20.4, 15.3, 5.1 Hz, 1H, PCH_a H _b), 4.07–4.19 (m, 4H, CH₃CH ₂OP), 4.37–4.50 (m, 1H, PCCH), 4.99 (dd, J = 13.5, 8.1 Hz, 1H, PCCCH _aH_b), 5.02 (dd, J = 13.5, 4.2 Hz, 1H, PCCCH_a H _b) ppm; ¹³C NMR (CD₃OD, 75 MHz): δ = 16.9 (d, J = 6.3 Hz, CCOP), 32.3 (d, J = 141.7 Hz, PC), 58.1 (d, J = 18.0 Hz, PCCC), 63.4 and 63.7 (2 d, J = 6.6 Hz, CCOP), 67.0 (d, J = 4.0 Hz, PCC), 132.6 and 140.4 (2 s, C=C), 160.6 and 165.3 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 121 MHz): δ = 30.1 ppm.

Diethyl 3-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)-1-hydroxypropylphosphonate (9f, C₁₁H₂₀N₅O₆P)

From 0.180 g diester 8f (0.475 mmol) diamide 9f was obtained as a white amorphous solid (0.093 g, 56 %) after crystallisation from methanol. M.p.: 179–180 °C; IR (KBr): $\overline{V}$ = 3,433, 3,319, 3,212, 2,974, 2,930, 2,874, 1,668, 1,605, 1,455, 1,399, 1,221, 1,167, 1,066, 1,014, 953 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz): δ = 1.32 (t, J = 7.2 Hz, 6H, CH ₃CH₂OP), 2.13–2.28 (m, 1H, PCCH _aH_b), 2.31–2.44 (m, 1H, PCCH_a H _b), 3.89 (ddd, J = 10.5, 7.2, 3.0 Hz, 1H, PCH), 4.10–4.21 (m, 4H, CH₃CH ₂OP), 4.95–5.14 (m, 2H, CH₂N) ppm; solubility of 9f in D₂O or CD₃OD was not sufficient to measure the ¹³C NMR spectrum; ³¹P NMR (CD₃OD, 121 MHz): δ = 25.4 ppm.

Diethyl 2-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)-1-hydroxyethylphosphonate (9g, C₁₀H₁₈N₅O₆P)

From 0.230 g diester 8g (0.630 mmol) diamide 9g was obtained as a white amorphous solid (0.112 g, 53 %) after chromatography on a silica gel column with chloroform/methanol (20:1, v/v) and crystallisation from methanol. M.p.: 200–202 °C; IR (KBr): $\overline{V}$ = 3,431, 3,223, 3,081, 2,990, 2,847, 1,671, 1,599, 1,452, 1,393, 1,289, 1,225, 1,031, 979 cm⁻¹; ¹H NMR (CD₃OD, 600 MHz): δ = 1.39 and 1.40 (2 t, J = 7.2 Hz, 6H, CH ₃CH₂OP), 4.22-4.29 (m, 4H, CH₃CH ₂OP), 4.55 (ddd, J = 10.2, 9.9 Hz, 3.6 Hz, 1H, PCH), 5.10 (ddd, J = 13.5, 10.2, 8.7 Hz, 1H, PCCH _aH_b), 5.22 (ddd, J = 13.5, 3.6, 3.1 Hz, 1H, PCCH_a H _b) ppm; solubility of 9g in D₂O and CD₃OD was not sufficient to measure the ¹³C NMR spectrum; ³¹P NMR (CD₃OD, 243 MHz): δ = 21.2 ppm.

Synthesis of dihydrazides 10a–10g (general procedure)

A solution of the diester 8a–8g (0.73 mmol) and 0.530 cm³ hydrazine hydrate (10.8 mmol) in 6 cm³ ethanol was refluxed for 2 h. The reaction mixtures were concentrated to give yellow oils or solids which were subjected to chromatography on a silica gel column with chloroform/methanol or crystallisation to obtain dihydrazides 10a–10g.

Diethyl 2-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-yl]ethylphosphonate (10a, C₁₀H₂₀N₇O₅P)

From 0.115 g diester 8a (0.330 mmol) dihydrazide 10a was obtained (0.070 g, 61 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, 10:1, v/v) as a white amorphous solid. M.p.: 84–86 °C; IR (KBr): $\overline{V}$ = 3,335, 3,282, 2,984, 2,932, 1,661, 1,606, 1,551, 1,491, 1,262, 1,223, 1,056, 1,020, 963 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz): δ = 1.32 (t, J = 6.6 Hz, 6H, CH ₃CH₂O), 2.48–2.59 (m, 2H, PCH₂), 4.07–4.18 (m, 4H, CH₃CH ₂O), 5.03–5.14 (m, 2H, CH₂N) ppm; ¹³C NMR (CD₃OD, 75 MHz): δ = 16.9 (d, J = 6.0 Hz, CCOP), 27.4 (d, J = 140.0 Hz, PC), 47.1 (s, PCCN), 63.8 (d, J = 6.3 Hz, CCOP × 2), 130.8 and 139.3 (2 s, C=C), 157.6 and 161.8 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 121 MHz): δ = 28.2 ppm.

Diethyl 3-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-yl]propylphosphonate (10b, C₁₁H₂₂N₇O₅P)

From 0.170 g diester 8b (0.468 mmol) dihydrazide 10b was obtained as a white amorphous solid (0.113 g, 66 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, 10:1, v/v). M.p.: 73–75 °C; IR (KBr): $\overline{V}$ = 3,300, 3,192, 2,983, 2,931, 1,656, 1,551, 1,209, 1,024, 969 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.28 (t, J = 6.9 Hz, 6H, CH ₃CH₂OP), 1.71–1.82 (m, 2H, PCH₂CH ₂), 2.13–2.27 (m, 2H, PCH₂), 4.00–4.13 (m, 4H, CH₃CH ₂OP), 4.94 (t, J = 7.2 Hz, 2H, CH₂N), 5.15–6.03 (brs, 6H, NHNH₂) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.7 (d, J = 6.0 Hz, CCOP), 22.9 (d, J = 139.9 Hz, PC), 23.9 (d, J = 7.4 Hz, PCC), 51.8 (d, J = 18.9 Hz, PCCC), 62.0 (d, J = 6.6 Hz, CCOP), 129.5 and 137.6 (2 s, C=C), 156.3 and 161.3 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 31.5 ppm.

Diethyl [2-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-yl]ethoxy]methylphosphonate (10c, C₁₁H₂₂N₇O₆P)

From 0.430 g diester 8c (1.13 mmol) dihydrazide 10c was obtained as a colourless oil (0.139 g, 32 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, 10:1, v/v). IR (film): $\overline{V}$ = 3,326, 3,248, 2,985, 2,918, 2,890, 1,666, 1,544, 1,440, 1,300, 1,238, 1,117, 1,024, 968 cm⁻¹; ¹H NMR (CD₃OD, 600 MHz): δ = 1.28 (t, J = 7.0 Hz, 6H, CH ₃CH₂OP), 3.89 (d, J = 8.5 Hz, 2H, PCH₂), 4.05–4.10 (m, 6H, CH₃CH ₂OP and OCH ₂CH₂N), 5.14 (t, J = 4.8 Hz, 2H, OCH₂CH ₂N) ppm; ¹³C NMR (CD₃OD, 150 MHz): δ = 15.3 (d, J = 5.5 Hz, CCOP), 50.2 (s, CN), 62.8 (d, J = 6.5 Hz, CCOP), 64.0 (d, J = 164.9 Hz, PC), 71.1 (d, J = 11.9 Hz, PCOC), 129.9 and 137.9 (2 s, C=C), 156.5 and 160.5 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 243 MHz): δ = 21.4 ppm.

Diethyl 2-[2-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-yl]ethoxy]ethylphosphonate (10d, C₁₂H₂₄N₇O₆P)

From 0.216 g diester 8d (0.549 mmol) dihydrazide 10d was obtained as a white amorphous solid (0.128 g, 59 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, v/v) and crystallisation from ethyl acetate. M.p: 95–96 °C; IR (KBr): $\overline{V}$ = 3,300, 3,232, 2,983, 2,913, 2,827, 1,667, 1,545, 1,550, 1,252, 1,023, 966, 918 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.31 (t, J = 7.2 Hz, 6H, CH ₃CH₂OP), 2.03 (dt, J = 15.0, 7.5 Hz, 2H, PCH₂), 3.69 (dt, J = 11.1, 7.5 Hz, 2H, PCH₂CH ₂O), 3.91 (t, J = 5.7 Hz, 2H, OCH ₂CH₂N), 4.01–4.13 (m, 4H, CH₃CH ₂OP), 4.20 (brs, 4H, NH₂), 5.13 (t, J = 5.7 Hz, 2H, OCH₂CH ₂N), 8.81 (s, 1H, NH), 12.0 (s, 1H, NH) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.6 (d, J = 6.0 Hz, CCOP), 27.0 (d, J = 138.5 Hz, PC), 51.0 (s, OCCN), 61.9 (d, J = 6.3 Hz, CCOP), 65.0 (s, PCCO), 69.1 (s, OCCN), 129.9 and 137.5 (2 s, C=C), 156.5 and 161.3 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 28.5 ppm.

Diethyl 3-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-yl]-2-hydroxypropylphosphonate (10e, C₁₁H₂₂N₇O₆P)

From 0.290 g diester 8e (0.764 mmol) dihydrazide 10e was obtained as a white amorphous solid (0.140 g, 48 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, v/v) and crystallisation from ethanol. M.p.: 140–142 °C; IR (KBr): $\overline{V}$ = 3,336, 3,275, 2,980, 2,930, 1,668, 1,578, 1,549, 1,443,1,260, 1,217, 1,067, 1,027, 957 cm⁻¹; ¹H NMR (CD₃OD, 600 MHz): δ = 1.34 and 1.35 (2 t, J = 7.1 Hz, 6H, CH ₃CH₂OP), 2.12 (ddd, J = 23.6, 15.4, 8.2 Hz, 1H, PCH _aH_b), 2.18 (ddd, J = 20.1, 15.4, 4.7 Hz, 1H, PCH_a H _b), 4.11–4.19 (m, 4H, CH₃CH ₂OP), 4.44–4.47 (m, 1H, PCCH), 4.96 (dd, J = 13.4, 8.4 Hz, 1H, PCCCH _aH_b), 5.05 (dd, J = 13.4, 4.1 Hz, 1H, PCCCH_a H _b) ppm; ¹³C NMR (CD₃OD, 150 MHz): δ = 15.3 (d, J = 5.8 Hz, CCOP), 30.8 (d, J = 141.6 Hz, PC), 56.4 (d, J = 17.3 Hz, PCCC), 61.9 and 62.2 (2 d, J = 6.5 Hz, CCOP), 65.6 (d, J = 3.6 Hz, PCC), 130.1 and 137.9 (2 s, C=C), 156.7 and 160.6 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 243 MHz): δ = 28.9 ppm.

Diethyl 3-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-yl]-1-hydroxypropylphosphonate (10f, C₁₁H₂₂N₇O₆P)

From 0.262 g diester 8f (0.691 mmol) dihydrazide 10f was obtained as a white amorphous solid (0.155 g, 60 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 30:1, v/v). M.p.: 119–120 °C; IR (KBr): $\overline{V}$ = 3,316, 3,266, 3,160, 2,976, 2,930, 1,659, 1,572, 1,532, 1,249, 1,210, 1,072, 1,022, 955 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz): δ = 1.31 (t, J = 7.5 Hz, 6H, CH ₃CH₂OP), 2.13-2.29 (m, 1H, PCCH _aH_b), 2.31–2.44 (m, 1H, PCCH_a H _b), 3.91 (ddd, J = 10.8, 7.8, 3.3 Hz, 1H, PCH), 4.09–4.21 (m, 4H, CH₃CH ₂OP), 4.96–5.15 (m, 2H, CH₂N) ppm; ¹³C NMR (CD₃OD, 75 MHz): δ = 17.0 (d, J = 5.4 Hz, CCOP), 33.4 (s, PCC), 48.4 (d, J = 18.9 Hz, PCCC), 64.2 and 64.5 (d, J = 7.1 Hz, CCOP), 65.6 (d, J = 166.7 Hz, PC), 130.9 and 139.2 (2 s, C=C), 157.7 and 161.8 (2 s, C=O × 2) ppm; ³¹P NMR (CD₃OD, 121 MHz): δ = 25.5 ppm.

Diethyl 2-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-yl]-1-hydroxyethylphosphonate (10g, C₁₀H₂₀N₇O₆P)

From 0.450 g diester 8g (1.23 mmol) dihydrazide 10g was obtained as a white amorphous solid (0.128 g, 28 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 30:1, v/v). M.p.: 149–152 °C; IR (KBr): $\overline{V}$ = 3,334, 3,207, 2,980, 2,930, 2,870, 1,668, 1,578, 1,449, 1,217, 1,067, 1,028, 953 cm⁻¹; ¹H NMR (D₂O, 600 MHz): δ = 1.31 (t, J = 7.0 Hz, 6H, CH ₃CH₂OP), 4.18–4.24 (m, 4H, CH₃CH ₂OP), 4.53–4.58 (m, 1H, PCH), 4.94–5.01 (m, 1H, PCCH _aH_b), 5.11–5.16 (m, 1H, PCCH_a H _b) ppm; ¹³C NMR (D₂O, 150 MHz): δ = 15.7 (d, J = 4.6 Hz, CCOP), 51.9 (d, J = 11.2 Hz, PCCN), 64.7 and 64.8 (2 d, J = 7.4 Hz, CCOP), 65.5 (d, J = 165.8 Hz, PC), 130.4 and 137.5 (2 s, C=C), 156.5 and 160.2 (2 s, C=O) ppm; ³¹P NMR (D₂O, 243 MHz): δ = 21.8 ppm.

Synthesis of 1,2,3-triazolopyridazinediones 11a–11g (general procedure)

A mixture of the dihydrazide 10a–10g (0.50 mmol) and 5 cm³ 10 % hydrochloric acid was heated at 90 °C for 2.5 h. After concentration in vacuo, crude products were purified on a silica gel column with chloroform/methanol or crystallised from the appropriate solvent.

Diethyl 2-(4,7-dioxo-5,6-dihydro-1H-1,2,3-triazolo[4,5-d]pyridazin-1-yl)ethylphosphonate (11a, C₁₀H₁₆N₅O₅P)

From 0.167 g dihydrazide 10a (0.478 mmol) compound 11a was obtained as a white amorphous solid (0.045 g, 30 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, 10:1, v/v) followed by crystallisation from ethanol. M.p.: 198–200 °C; IR (KBr): $\overline{V}$ = 3,385, 2,922, 2,672, 1,687, 1,582, 1,460, 1,262, 1,214, 1,014, 1,019, 980 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz): δ = 1.28 (t, J = 6.6 Hz, 6H, CH ₃CH₂OP), 2.58 (dt, J = 14.7 Hz, J = 7.5 Hz, PCH₂), 4.03–4.13 (m, 4H, CH₃CH ₂OP), 5.12 (dt, J = 12.6 Hz, J = 7.5 Hz, CH₂N) ppm; ¹³C NMR (CD₃OD, 150 MHz): δ = 17.5 (d, J = 5.7 Hz, CCOP), 28.2 (d, J = 141.0 Hz, PC), 46.5 (d, J = 3.0 Hz, PCCN), 64.7 (d, J = 6.6 Hz, CCOP), 131.3 and 141.8 (2 s, C=C), 152.0 and 154.6 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 121 MHz): δ = 27.7 ppm.

Diethyl 3-(4,7-dioxo-5,6-dihydro-1H-1,2,3-triazolo[4,5-d]pyridazin-1-yl)propylphosphonate (11b, C₁₁H₁₈N₅O₅P)

From 0.055 g dihydrazide 10b (0.151 mmol) compound 11b was obtained as a white amorphous solid (0.033 g, 66 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, 10:1, v/v). M.p.: 148–150 °C; IR (KBr): $\overline{V}$ = 3,446, 3,074, 2,991, 2,960, 1,662, 1,555, 1,462, 1,294, 1,218, 1,032, 972, 805 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz): δ = 1.31 (t, J = 6.9 Hz, 6H, CH ₃CH₂OP), 1.84–1.95 (m, 2H, PCH₂CH ₂), 2.24–2.38 (m, 2H, PCH₂), 4.02–4.15 (m, 4H, CH₃CH ₂OP), 4.93 (t, J = 6.9 Hz, 2H, CH₂N) ppm; ¹³C NMR (CD₃OD, 75 MHz): δ = 16.7 (d, J = 5.7 Hz, CCOP), 22.7 (d, J = 141.9 Hz, PC), 23.9 (s, PCC), 50.5 (d, J = 18.5 Hz, PCCC), 62.6 (d, J = 6.5 Hz, CCOP), 129.1 and 139.7 (2 s, C=C), 150.5 and 152.7 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 121 MHz): δ = 32.6 ppm.

Diethyl [2-(4,7-dioxo-5,6-dihydro-1H-1,2,3-triazolo[4,5-d]pyridazin-1-yl)ethoxy]methylphosphonate (11c, C₁₁H₁₈N₅O₆P)

From 0.090 g dihydrazide 10c (0.237 mmol) compound 11c was obtained as a white amorphous solid (0.043 g, 52 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, v/v). M.p.: 170–172 °C; IR (KBr): $\overline{V}$ = 3,348, 2,985, 2,930, 2,918, 1,658, 1,552, 1,420, 1,260, 1,070, 1,028, 975 cm⁻¹; ¹H NMR (CD₃OD, 600 MHz): δ = 1.25 (t, J = 7.0 Hz, 6H, CH ₃CH₂OP), 3.89 (d, J = 8.5 Hz, 2H, PCH₂), 4.01–4.04 (m, 4H, CH₃CH ₂OP), 4.16 (t, J = 5.1 Hz, 2H, OCH ₂CH₂N), 5.09 (t, J = 5.1 Hz, 2H, OCH₂CH ₂N) ppm; ¹³C NMR (CD₃OD, 150 MHz): δ = 15.2 (d, J = 5.7 Hz, CCOP), 49.2 (s, CN), 62.7 (d, J = 6.6 Hz, CCOP), 63.9 (d, J = 164.8 Hz, PC), 70.9 (d, J = 12.1 Hz, PCOC), 129.2 and 139.3 (2 s, C=C), 149.6 and 152.3 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 243 MHz): δ = 21.2 ppm.

Diethyl 2-[2-(4,7-dioxo-5,6-dihydro-1H-1,2,3-triazolo[4,5-d]pyridazin-1-yl)ethoxy]ethylphosphonate (11d, C₁₂H₂₀N₅O₆P)

From 0.165 g dihydrazide 10d (0.419 mmol) compound 11d was obtained as a white amorphous solid (0.087 g, 58 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, v/v) and crystallisation from ethyl acetate/chloroform. M.p.: 134–135 °C; IR (KBr): $\overline{V}$ = 3,433, 2,974, 2,928, 2,872, 1,715, 1,645, 1,206, 1,113, 1,065, 1,026, 982, 952 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ = 1.26 (t, J = 7.2 Hz, 6H, CH ₃CH₂OP), 2.07 (dt, J = 15.0, 7.2 Hz, 2H, PCH₂), 3.73 (dt, J = 13.5, 7.5 Hz, 2H, PCH₂CH ₂O), 3.96–4.10 (m, 6H, CH₃CH ₂OP and OCH ₂CH₂N), 5.01 (t, J = 5.1 Hz, 2H, OCH₂CH ₂N), 10.49 (brs, 2H, NH) ppm; ¹³C NMR (CDCl₃, 75 MHz): δ = 16.6 (d, J = 6.3 Hz, CCOP), 26.8 (d, J = 138.9 Hz, PC), 49.9 (s, OCCN), 62.2 (d, J = 6.5 Hz, CCOP), 65.0 (s, PCCO), 68.8 (s, OCCN), 129.4 and 139.4 (2 s, C=C), 151.1 and 152.8 (2 s, C=O) ppm; ³¹P NMR (CDCl₃, 121 MHz): δ = 29.3 ppm.

Diethyl 3-(4,7-dioxo-5,6-dihydro-1H-1,2,3-triazolo[4,5-d]pyridazin-1-yl)-2-hydroxypropylphosphonate (11e, C₁₁H₁₈N₅O₆P)

From 0.270 g dihydrazide 10e (0.719 mmol) compound 11e was obtained as a white amorphous solid (0.087 g, 39 %) after chromatography on a silica gel column with chloroform/methanol (20:1, 10:1, v/v) and crystallisation from water. M.p.: 168–170 °C; IR (KBr): $\overline{V}$ = 3,476, 2,982, 2,932, 2,867, 1,655, 1,550, 1,427, 1,405, 1,256, 1,222, 1,108, 1,054, 957 cm⁻¹; ¹H NMR (D₂O, 600 MHz): δ = 1.30 and 1.31 (2 t, J = 6.1 Hz, 6H, CH ₃CH₂OP), 2.25 (td, J = 16.1, 8.8 Hz, 1H, PCH _aH_b), 2.35 (td, J = 15.8, 3.2 Hz, 1H, PCH_a H _b), 4.10–4.17 (m, 4H, CH₃CH ₂OP), 4.52–4.59 (m, 1H, PCCH), 4.91 (dd, J = 12.8, 9.2 Hz, 1H, PCCCH _aH_b), 4.98 (dd, J = 12.8, 2.6 Hz, 1H, PCCCH_a H _b) ppm; ¹³C NMR (D₂O, 150 MHz): δ = 15.6 (d, J = 5.7 Hz, CCOP), 30.0 (d, J = 139.9 Hz, PC), 55.7 (d, J = 17.8 Hz, PCCC), 63.5 and 63.6 (2 d, J = 6.4 Hz, CCOP), 65.4 (d, J = 3.8 Hz, PCC), 130.1 and 140.1 (2 s, C=C), 149.8 and 153.4 (2 s, C=O) ppm; ³¹P NMR (D₂O, 243 MHz): δ = 30.3 ppm.

Diethyl 3-(4,7-dioxo-5,6-dihydro-1H-1,2,3-triazolo[4,5-d]pyridazin-1-yl)-1-hydroxypropylphosphonate (11f, C₁₁H₁₈N₅O₆P)

From 0.163 g dihydrazide 10f (0.430 mmol) compound 11f was obtained as a white amorphous solid (0.086 g, 58 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 20:1, 10:1, v/v). M.p.: 66–68 °C; IR (KBr): $\overline{V}$ = 3,362, 2,987, 2,920, 1,666, 1,580, 1,449, 1,212, 1,050, 1,021, 970 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz): δ = 1.32 (t, J = 7.2 Hz, 6H, CH ₃CH₂OP), 2.19–2.28 (m, 1H, PCCH _aH_b), 2.31–2.44 (m, 1H, PCCH_a H _b), 3.89 (ddd, J = 10.5, 7.2, 3.0 Hz, 1H, PCH), 4.10–4.21 (m, 4H, CH₃CH ₂OP), 4.95–5.12 (m, 2H, CH₂N) ppm; ¹³C NMR (CD₃OD, 75 MHz): δ = 17.0 (d, J = 5.4 Hz, CCOP), 33.3 (d, J = 4.0 Hz, PCC), 48.1 (d, J = 16.2 Hz, PCCC), 64.2 and 64.5 (d, J = 6.9 Hz, CCOP), 65.4 (d, J = 167.3 Hz, PC), 130.2 and 140.8 (2 s, C=C), 148.9 and 152.2 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 121 MHz): δ = 25.3 ppm.

Diethyl 2-(4,7-dioxo-5,6-dihydro-1H-1,2,3-triazolo[4,5-d]pyridazin-1-yl)-1-hydroxyethylphosphonate (11g, C₁₀H₁₆N₅O₆P)

From 0.100 g dihydrazide 10g (0.274 mmol) compound 11g was obtained as a colourless oil (0.036 g, 40 %) after chromatography on a silica gel column with chloroform/methanol (50:1, 10:1, v/v). IR (film): $\overline{V}$ = 3,362, 2,988, 2,971, 1,667, 1,580, 1,212, 1,021 cm⁻¹; ¹H NMR (CD₃OD, 600 MHz): δ = 1.38 and 1.39 (2 t, J = 7.0 Hz, 6H, CH ₃CH₂OP), 4.23–4.29 (m, 4H, CH₃CH ₂OP), 4.64–4.69 (m, 1H, PCH), 5.09–5.15 (m, 2H, CH₂N) ppm; ¹³C NMR (CD₃OD, 150 MHz): δ = 15.3 and 15.4 (d, J = 5.2 Hz, CCOP), 51.3 (d, J = 11.6 Hz, PCCN), 63.3 and 63.5 (2 d, J = 6.8 Hz, COP), 66.4 (d, J = 166.2 Hz, PC), 129.2 and 139.4 (2 s, C=C), 150.1 and 152.4 (2 s, C=O) ppm; ³¹P NMR (CD₃OD, 243 MHz): δ = 20.5 ppm.

Assays for antiviral activity other than HIV

The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK⁻) HSV-1 KOS strain resistant to ACV (ACV^r), herpes simplex virus type 2 (HSV-2) strain G, cytomegalovirus (strains AD-169 and Davis), varicella-zoster virus (VZV) (strains OKA and YS), vaccinia virus Lederle strain, respiratory syncytial virus (RSV) strain Long, vesicular stomatitis virus (VSV), coxsackie b4 virus, parainfluenza 3, influenza virus A (subtypes H1N1, H3N2), influenza virus B, reovirus-1, Sindbis virus and Punta Toro virus. The antiviral assays were based on inhibition of virus-induced cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero), human epithelial cervix carcinoma cells (HeLa) or MDCK. Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID₅₀ of virus (1 CCID₅₀ being the virus dose to infect 50 % of the cell cultures) or 20 or 100 plaque forming units (PFU) (for VZV and CMV, respectively) in the presence of varying concentrations of the test compounds. Viral cytopathicity or plaque formation was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds. Antiviral activity was expressed as the EC₅₀ or compound concentration required to reduce virus-induced cytopathogenicity or viral plaque formation by 50 %.

Anti-HIV activity assays

Inhibition of HIV-1(III_B)- and HIV-2(ROD)-induced cytopathicity in CEM cell cultures was measured in microtiter 96-well plates containing 3 × 10⁵ CEM cells/cm³ infected with 100 CCID50 of HIV per cm³ and containing appropriate dilutions of the test compounds. After 4–5 days of incubation at 37 °C in a CO₂-controlled humidified atmosphere, CEM giant cell (syncytium) formation was examined microscopically. The EC₅₀ (50 % effective concentration) was defined as the compound concentration required to inhibit HIV-induced giant cell formation by 50 %.

Cytostatic activity assays

All assays were performed in 96-well microtiter plates. To each well were added (5–7.5) × 10⁴ tumour cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 37 °C in a humidified CO₂-controlled atmosphere. At the end of the incubation period, the cells were counted in a Coulter counter. The IC₅₀ (50 % inhibitory concentration) was defined as the concentration of the compound that inhibited cell proliferation by 50 %.

Electronic supplementary material

Below is the link to the electronic supplementary material.